N-butyldeoxynojirimycin treatment restores the innate fear response and improves learning in mucopolysaccharidosis IIIA mice

Neufield, 2001, The mucopolysaccharidoses, 3421 Inokuchi, 1987, Preparation of the active isomer of 1-phenyl-2-decanoylamino-3-morpholino-1-propanol, inhibitor of murine glucocerebroside synthetase, J. Lipid Res., 28, 565, 10.1016/S0022-2275(20)38673-9 Piotrowska, 2011, Two-year follow-up of Sanfilippo disease patients treated with a genistein-rich isoflavone extract: assessment of effects on cognitive functions and general status of patients, Med. Sci. Monit., 17, CR196, 10.12659/MSM.881715 Piotrowska, 2008, Genistin-rich soy isoflavone extract in substrate reduction therapy for Sanfilippo syndrome: an open-label, pilot study in 10 pediatric patients, Curr. Ther. Res. Clin. Exp., 69, 166, 10.1016/j.curtheres.2008.04.002 Roberts, 2007, Improvement in behaviour after substrate deprivation therapy with rhodamine B in a mouse model of MPS IIIA, Mol. Genet. Metab., 92, 115, 10.1016/j.ymgme.2007.06.016 Roberts, 2006, Inhibition of glycosaminoglycan synthesis using rhodamine B in a mouse model of mucopolysaccharidosis type IIIA, Pediatr. Res., 60, 309, 10.1203/01.pdr.0000233037.00707.da Friso, 2009, Genistein reduces glycosaminoglycan levels in a mouse model of mucopolysaccharidosis type II, Br. J. Pharmacol., 159, 1082, 10.1111/j.1476-5381.2009.00565.x Malinowska, 2010, Genistein improves neuropathology and corrects behaviour in a mouse model of neurodegenerative metabolic disease, PLoS One, 5, e14192, 10.1371/journal.pone.0014192 Constantopoulos, 1978, Neurochemistry of the mucopolysaccharidoses: brain lipids and lysosomal enzymes in patients with four types of mucopolysaccharidosis and in normal controls, J. Neurochem., 30, 965, 10.1111/j.1471-4159.1978.tb12388.x Constantopoulos, 1980, Mucopolysaccharidosis types IH, IS, II, and IIIA: glycosaminoglycans and lipids of isolated brain cells and other fractions from autopsied tissues, J. Neurochem., 34, 1399, 10.1111/j.1471-4159.1980.tb11220.x Constantopoulos, 1976, Neurochemistry of the mucopolysaccharidoses: brain glycosaminoglycans in normals and four types of mucopolysaccharidoses, J. Neurochem., 26, 901, 10.1111/j.1471-4159.1976.tb06471.x McGlynn, 2004, Differential subcellular localization of cholesterol, gangliosides, and glycosaminoglycans in murine models of mucopolysaccharide storage disorders, J. Comp. Neurol., 480, 415, 10.1002/cne.20355 Gravel, 2001, The GM2 gangliosidoses, 3827 Purpura, 1976, Distortion of neuronal geometry and formation of aberrant synapses in neuronal storage disease, Brain Res., 116, 1, 10.1016/0006-8993(76)90245-6 Dekaban, 1977, Mucopolysaccharidosis type I, II, IIIA and V. Pathological and biochemical abnormalities in the neural and mesenchymal elements of the brain, Acta Neuropathol., 39, 1, 10.1007/BF00690379 Platt, 1994, N-butyldeoxynojirimycin is a novel inhibitor of glycolipid biosynthesis, J. Biol. Chem., 269, 8362, 10.1016/S0021-9258(17)37202-2 Platt, 1997, Prevention of lysosomal storage in Tay-Sachs mice treated with N-butyldeoxynojirimycin, Science, 276, 428, 10.1126/science.276.5311.428 Platt, 1997, Extensive glycosphingolipid depletion in the liver and lymphoid organs of mice treated with N-butyldeoxynojirimycin, J. Biol. Chem., 272, 19365, 10.1074/jbc.272.31.19365 Santos-Lozano, 2015, Niemann-Pick disease treatment: a systematic review of clinical trials, Ann Transl Med, 3, 360 Patterson, 2015, N.P.C.R. investigators, Stable or improved neurological manifestations during miglustat therapy in patients from the international disease registry for Niemann-Pick disease type C: an observational cohort study, Orphanet J. Rare Dis., 10, 65, 10.1186/s13023-015-0284-z Wraith, 2009, New therapies in the management of Niemann-Pick type C disease: clinical utility of miglustat, Ther. Clin. Risk Manag., 5, 877, 10.2147/TCRM.S5777 Cox, 2003, The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease: a position statement, J. Inherit. Metab. Dis., 26, 513, 10.1023/A:1025902113005 Maegawa, 2009, Substrate reduction therapy in juvenile GM2 gangliosidosis, Mol. Genet. Metab., 98, 215, 10.1016/j.ymgme.2009.06.005 Shapiro, 2009, Miglustat in late-onset Tay-Sachs disease: a 12-month, randomized, controlled clinical study with 24months of extended treatment, Genet. Med., 11, 425, 10.1097/GIM.0b013e3181a1b5c5 Masciullo, 2010, Substrate reduction therapy with miglustat in chronic GM2 gangliosidosis type Sandhoff: results of a 3-year follow-up, J. Inherit. Metab. Dis., 10.1007/s10545-010-9186-3 Tallaksen, 2009, Miglustat therapy in juvenile Sandhoff disease, J. Inherit. Metab. Dis., 10.1007/s10545-009-1224-7 Wortmann, 2009, Substrate deprivation therapy in juvenile Sandhoff disease, J. Inherit. Metab. Dis., 32, S307, 10.1007/s10545-009-1261-2 Schiffmann, 2008, Randomized, controlled trial of miglustat in Gaucher's disease type 3, Ann. Neurol., 64, 514, 10.1002/ana.21491 Guffon, 2011, Evaluation of miglustat treatment in patients with type III mucopolysaccharidosis: a randomized, double-blind, placebo-controlled study, J. Pediatr., 159, 838, 10.1016/j.jpeds.2011.04.040 Zervas, 2001, Neurons in Niemann-Pick disease type C accumulate gangliosides as well as unesterified cholesterol and undergo dendritic and axonal alterations, J. Neuropathol. Exp. Neurol., 60, 49, 10.1093/jnen/60.1.49 Roberts, 2009, Gastrointestinal pathology in a mouse model of mucopolysaccharidosis type IIIA, J. Cell. Physiol., 219, 259, 10.1002/jcp.21682 Hoff, 2000, Methods of blood collection in the mouse, Lab Animal, 47 Derrick-Roberts, 2014, Lentiviral-mediated gene therapy results in sustained expression of β-glucuronidase for up to 12months in the gus(mps/mps) and up to 18months in the gus(tm(L175F)Sly) mouse models of mucopolysaccharidosis type VII, Hum. Gene Ther., 25, 798, 10.1089/hum.2013.141 Macsai, 2012, Skeletal response to lentiviral mediated gene therapy in a mouse model of MPS VII, Mol. Genet. Metab., 106, 202, 10.1016/j.ymgme.2012.03.022 Ichikawa, 1996, Expression cloning of a cDNA for human ceramide glucosyltransferase that catalyzes the first glycosylation step of glycosphingolipid synthesis, Proc. Natl. Acad. Sci. U. S. A., 93, 4638, 10.1073/pnas.93.10.4638 Folch, 1957, A simple method for the isolation and purification of total lipides from animal tissues, J. Biol. Chem., 226, 497, 10.1016/S0021-9258(18)64849-5 Williams, 1980, The use of Sep-Pak C18 cartridges during the isolation of gangliosides, J. Neurochem., 35, 266, 10.1111/j.1471-4159.1980.tb12515.x Blumenkrantz, 1973, New method for quantitative determination of uronic acids, Anal. Biochem., 54, 484, 10.1016/0003-2697(73)90377-1 Arfi, 2011, Neuroinflammatory and oxidative stress phenomena in MPS IIIA mouse model: The positive effect of long-term aspirin treatment, Mol. Genet. Metab., 10.1016/j.ymgme.2011.01.015 DiRosario, 2009, Innate and adaptive immune activation in the brain of MPS IIIB mouse model, J. Neurosci. Res., 87, 978, 10.1002/jnr.21912 Ohmi, 2003, Activated microglia in cortex of mouse models of mucopolysaccharidoses I and IIIB, Proc. Natl. Acad. Sci. U. S. A., 100, 1902, 10.1073/pnas.252784899 Richard, 2008, Identification of new markers for neurodegeneration process in the mouse model of Sly disease as revealed by expression profiling of selected genes, J. Neurosci. Res., 86, 3285, 10.1002/jnr.21779 Villani, 2007, Cytokines, neurotrophins, and oxidative stress in brain disease from mucopolysaccharidosis IIIB, J. Neurosci. Res., 85, 612, 10.1002/jnr.21134 Ohmi, 2009, Sanfilippo syndrome type B, a lysosomal storage disease, is also a tauopathy, Proc. Natl. Acad. Sci. U. S. A., 106, 8332, 10.1073/pnas.0903223106 Livak, 2001, Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method, Methods, 25, 402, 10.1006/meth.2001.1262 Ashe, 2011, Iminosugar-based inhibitors of glucosylceramide synthase increase brain glycosphingolipids and survival in a mouse model of Sandhoff disease, PLoS One, 6, e21758, 10.1371/journal.pone.0021758 Jeyakumar, 1999, Delayed symptom onset and increased life expectancy in Sandhoff disease mice treated with N-butyldeoxynojirimycin, Proc. Natl. Acad. Sci. U. S. A., 96, 6388, 10.1073/pnas.96.11.6388 Jeyakumar, 2001, Enhanced survival in Sandhoff disease mice receiving a combination of substrate deprivation therapy and bone marrow transplantation, Blood, 97, 327, 10.1182/blood.V97.1.327 Nietupski, 2012, Iminosugar-based inhibitors of glucosylceramide synthase prolong survival but paradoxically increase brain glucosylceramide levels in Niemann-Pick C mice, Mol. Genet. Metab., 105, 621, 10.1016/j.ymgme.2012.01.020 Overkleeft, 1998, Generation of specific deoxynojirimycin-type inhibitors of the non-lysosomal glucosylceramidase, J. Biol. Chem., 273, 26522, 10.1074/jbc.273.41.26522 Platt, 1994, N-butyldeoxygalactonojirimycin inhibits glycolipid biosynthesis but does not affect N-linked oligosaccharide processing, J. Biol. Chem., 269, 27108, 10.1016/S0021-9258(18)47132-3 Ridley, 2013, β-Glucosidase 2 (GBA2) activity and imino sugar pharmacology, J. Biol. Chem., 288, 26052, 10.1074/jbc.M113.463562 Alfonso, 2005, Miglustat (NB-DNJ) works as a chaperone for mutated acid beta-glucosidase in cells transfected with several Gaucher disease mutations, Blood Cells Mol. Dis., 35, 268, 10.1016/j.bcmd.2005.05.007 Simon, 1994, Thigmotaxis as an index of anxiety in mice. Influence of dopaminergic transmissions, Behav. Brain Res., 61, 59, 10.1016/0166-4328(94)90008-6 Frisella, 2001, Intracranial injection of recombinant adeno-associated virus improves cognitive function in a murine model of mucopolysaccharidosis type VII, Mol. Ther., 3, 351, 10.1006/mthe.2001.0274 Vite, 2011, Biodistribution and pharmacodynamics of recombinant human alpha-l-iduronidase (rhIDU) in mucopolysaccharidosis type I-affected cats following multiple intrathecal administrations, Mol. Genet. Metab., 103, 268, 10.1016/j.ymgme.2011.03.011 Wolf, 2011, Direct gene transfer to the CNS prevents emergence of neurologic disease in a murine model of mucopolysaccharidosis type I, Neurobiol. Dis., 43, 123, 10.1016/j.nbd.2011.02.015 Elliot-Smith, 2008, Beneficial effects of substrate reduction therapy in a mouse model of GM1 gangliosidosis, Mol. Genet. Metab., 94, 204, 10.1016/j.ymgme.2008.02.005 Andersson, 2004, Improved outcome of N-butyldeoxygalactonojirimycin-mediated substrate reduction therapy in a mouse model of Sandhoff disease, Neurobiol. Dis., 16, 506, 10.1016/j.nbd.2004.04.012 Jeyakumar, 2003, Central nervous system inflammation is a hallmark of pathogenesis in mouse models of GM1 and GM2 gangliosidosis, Brain, 126, 974, 10.1093/brain/awg089 Boomkamp, 2010, Lysosomal storage of oligosaccharide and glycosphingolipid in imino sugar treated cells, Glycoconj. J., 27, 297, 10.1007/s10719-010-9278-1 Kan, 2014, Delivery of an enzyme-IGFII fusion protein to the mouse brain is therapeutic for mucopolysaccharidosis type IIIB, Proc. Natl. Acad. Sci. U. S. A., 111, 14870, 10.1073/pnas.1416660111 Valstar, 2011, Cognitive development in patients with Mucopolysaccharidosis type III (Sanfilippo syndrome), Orphanet J. Rare Dis., 6, 43, 10.1186/1750-1172-6-43